{
  "precedent_exists": true,
  "known_trials": [
    {
      "nct_id": "NCT02410733",
      "name": "BNT111",
      "sponsor": "BioNTech",
      "indication": "Melanoma",
      "approach": "Personalized neoantigen mRNA",
      "status": "Completed",
      "outcome": "Safe, induced immune responses"
    },
    {
      "nct_id": "NCT03313778",
      "name": "mRNA-4157",
      "sponsor": "Moderna",
      "indication": "Solid tumors",
      "approach": "Personalized neoantigen mRNA (up to 34 neoantigens)",
      "status": "Active",
      "outcome": "Combined with pembrolizumab, reduced recurrence in melanoma"
    },
    {
      "nct_id": "NCT03639714",
      "name": "SLATE",
      "sponsor": "Gritstone",
      "indication": "NSCLC, other solid tumors",
      "approach": "Shared + personalized neoantigens",
      "status": "Completed",
      "outcome": "Immune responses observed"
    }
  ],
  "key_papers": [
    "10.1038/s41586-021-03368-8",
    "10.1038/s41586-022-05400-5"
  ]
}